Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past Platinum - DNA adducts

Alexandra Vaisman, Susan E. Lim, Steve M. Patrick, William C. Copeland, David C. Hinkle, John Turchi, Stephen G. Chaney

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Translesion synthesis past Pt-DNA adducts can affect both the cytotoxicity and mutagenicity of the platinum adducts. We have shown previously that the extent of replicative bypass in vivo is influenced by the carrier ligand of platinum adducts. The specificity of replicative bypass may be determined by the DNA polymerase complexes that catalyze translesion synthesis past Pt-DNA adducts and/or by DNA damage-recognition proteins that bind to the Pt-DNA adducts and block translesion replication. In the present study, primer extension on DNA templates containing site-specifically placed cisplatin, oxaliplatin JM216, or chlorodiethylenetriamine-Pt adducts revealed that the eukaryotic DNA polymerases β, ζ, γ and human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) had a similar specificity for translesion synthesis past Pt-DNA adducts (dien >> oxaliplatin ≥ cisplatin > JM216). Primer extension assays performed in the presence of high mobility group protein 1 (HMG1), which is known to recognize cisplatin-damaged DNA, revealed that inhibition of translesion synthesis by HMG1 also depended on the carrier ligand of the Pt-DNA adduct (cisplatin > oxaliplatin = JM216 >> dien). These data were consistent with the results of gel-shift experiments showing similar differences in the affinity of HMG1 for DNA modified with the different platinum adducts. Our studies show that both DNA polymerases and damage-recognition proteins can impart specificity to replicative bypass of Pt-DNA adducts. This information may serve as a model for further studies of translesion synthesis.

Original languageEnglish (US)
Pages (from-to)11026-11039
Number of pages14
JournalBiochemistry
Volume38
Issue number34
DOIs
StatePublished - Aug 24 1999
Externally publishedYes

Fingerprint

oxaliplatin
High Mobility Group Proteins
DNA Adducts
DNA-Directed DNA Polymerase
Platinum
Ligands
Cisplatin
DNA
DNA Damage
Cytotoxicity
HIV-1
Assays
Proteins
Gels
satraplatin
Experiments

ASJC Scopus subject areas

  • Biochemistry

Cite this

Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past Platinum - DNA adducts. / Vaisman, Alexandra; Lim, Susan E.; Patrick, Steve M.; Copeland, William C.; Hinkle, David C.; Turchi, John; Chaney, Stephen G.

In: Biochemistry, Vol. 38, No. 34, 24.08.1999, p. 11026-11039.

Research output: Contribution to journalArticle

Vaisman, Alexandra ; Lim, Susan E. ; Patrick, Steve M. ; Copeland, William C. ; Hinkle, David C. ; Turchi, John ; Chaney, Stephen G. / Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past Platinum - DNA adducts. In: Biochemistry. 1999 ; Vol. 38, No. 34. pp. 11026-11039.
@article{a233554557ae43a7bff6e5298df36d26,
title = "Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past Platinum - DNA adducts",
abstract = "Translesion synthesis past Pt-DNA adducts can affect both the cytotoxicity and mutagenicity of the platinum adducts. We have shown previously that the extent of replicative bypass in vivo is influenced by the carrier ligand of platinum adducts. The specificity of replicative bypass may be determined by the DNA polymerase complexes that catalyze translesion synthesis past Pt-DNA adducts and/or by DNA damage-recognition proteins that bind to the Pt-DNA adducts and block translesion replication. In the present study, primer extension on DNA templates containing site-specifically placed cisplatin, oxaliplatin JM216, or chlorodiethylenetriamine-Pt adducts revealed that the eukaryotic DNA polymerases β, ζ, γ and human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) had a similar specificity for translesion synthesis past Pt-DNA adducts (dien >> oxaliplatin ≥ cisplatin > JM216). Primer extension assays performed in the presence of high mobility group protein 1 (HMG1), which is known to recognize cisplatin-damaged DNA, revealed that inhibition of translesion synthesis by HMG1 also depended on the carrier ligand of the Pt-DNA adduct (cisplatin > oxaliplatin = JM216 >> dien). These data were consistent with the results of gel-shift experiments showing similar differences in the affinity of HMG1 for DNA modified with the different platinum adducts. Our studies show that both DNA polymerases and damage-recognition proteins can impart specificity to replicative bypass of Pt-DNA adducts. This information may serve as a model for further studies of translesion synthesis.",
author = "Alexandra Vaisman and Lim, {Susan E.} and Patrick, {Steve M.} and Copeland, {William C.} and Hinkle, {David C.} and John Turchi and Chaney, {Stephen G.}",
year = "1999",
month = "8",
day = "24",
doi = "10.1021/bi9909187",
language = "English (US)",
volume = "38",
pages = "11026--11039",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "34",

}

TY - JOUR

T1 - Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past Platinum - DNA adducts

AU - Vaisman, Alexandra

AU - Lim, Susan E.

AU - Patrick, Steve M.

AU - Copeland, William C.

AU - Hinkle, David C.

AU - Turchi, John

AU - Chaney, Stephen G.

PY - 1999/8/24

Y1 - 1999/8/24

N2 - Translesion synthesis past Pt-DNA adducts can affect both the cytotoxicity and mutagenicity of the platinum adducts. We have shown previously that the extent of replicative bypass in vivo is influenced by the carrier ligand of platinum adducts. The specificity of replicative bypass may be determined by the DNA polymerase complexes that catalyze translesion synthesis past Pt-DNA adducts and/or by DNA damage-recognition proteins that bind to the Pt-DNA adducts and block translesion replication. In the present study, primer extension on DNA templates containing site-specifically placed cisplatin, oxaliplatin JM216, or chlorodiethylenetriamine-Pt adducts revealed that the eukaryotic DNA polymerases β, ζ, γ and human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) had a similar specificity for translesion synthesis past Pt-DNA adducts (dien >> oxaliplatin ≥ cisplatin > JM216). Primer extension assays performed in the presence of high mobility group protein 1 (HMG1), which is known to recognize cisplatin-damaged DNA, revealed that inhibition of translesion synthesis by HMG1 also depended on the carrier ligand of the Pt-DNA adduct (cisplatin > oxaliplatin = JM216 >> dien). These data were consistent with the results of gel-shift experiments showing similar differences in the affinity of HMG1 for DNA modified with the different platinum adducts. Our studies show that both DNA polymerases and damage-recognition proteins can impart specificity to replicative bypass of Pt-DNA adducts. This information may serve as a model for further studies of translesion synthesis.

AB - Translesion synthesis past Pt-DNA adducts can affect both the cytotoxicity and mutagenicity of the platinum adducts. We have shown previously that the extent of replicative bypass in vivo is influenced by the carrier ligand of platinum adducts. The specificity of replicative bypass may be determined by the DNA polymerase complexes that catalyze translesion synthesis past Pt-DNA adducts and/or by DNA damage-recognition proteins that bind to the Pt-DNA adducts and block translesion replication. In the present study, primer extension on DNA templates containing site-specifically placed cisplatin, oxaliplatin JM216, or chlorodiethylenetriamine-Pt adducts revealed that the eukaryotic DNA polymerases β, ζ, γ and human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) had a similar specificity for translesion synthesis past Pt-DNA adducts (dien >> oxaliplatin ≥ cisplatin > JM216). Primer extension assays performed in the presence of high mobility group protein 1 (HMG1), which is known to recognize cisplatin-damaged DNA, revealed that inhibition of translesion synthesis by HMG1 also depended on the carrier ligand of the Pt-DNA adduct (cisplatin > oxaliplatin = JM216 >> dien). These data were consistent with the results of gel-shift experiments showing similar differences in the affinity of HMG1 for DNA modified with the different platinum adducts. Our studies show that both DNA polymerases and damage-recognition proteins can impart specificity to replicative bypass of Pt-DNA adducts. This information may serve as a model for further studies of translesion synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0033600558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033600558&partnerID=8YFLogxK

U2 - 10.1021/bi9909187

DO - 10.1021/bi9909187

M3 - Article

C2 - 10460158

AN - SCOPUS:0033600558

VL - 38

SP - 11026

EP - 11039

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 34

ER -